Literature DB >> 2947644

Flow cytometric analysis of human bone marrow: I. Normal erythroid development.

M R Loken, V O Shah, K L Dattilio, C I Civin.   

Abstract

Flow cytometry was used to identify maturational differences of erythroid lineage cells in normal human bone marrow by combining physical characteristics, the expression of multiple cell surface antigens, and nucleic acid content. Normal low-density bone marrow cells could be divided into four populations, based on forward and right-angle light scattering. Erythroid cells, at different maturational stages, were found in three of these four marrow subpopulations. The sequentially correlated expression of three cell surface markers--HLe-1, transferrin receptor, and glycophorin--allowed us to study erythroid maturation from the colony forming cell to the mature erythrocyte. HLe-1 was expressed on the earliest identifiable erythroid cells and was progressively lost as the cells matured. Transferrin receptor began to be expressed at the BFU-E stage and disappeared at the late reticulocyte stage. Transferrin receptor expression preceded glycophorin expression, the latter beginning on morphologically recognizable erythroid precursors just after the CFU-E stage. In contrast to both HLe-1 and transferrin receptor, which were progressively lost during the maturational process, once glycophorin had been maximally expressed on the cell surface, it remained at constant quantities to the mature erythrocyte stage. Although developing nucleated erythroid cells at approximately the normoblast stage had light-scattering properties similar to those of lymphoid cells, these two cell types could be resolved by cell surface antigen expression. Normoblasts were glycophorin positive and HLe negative, whereas lymphoid cells expressed HLe and either Leu 4, Leu 11, or Leu 12. Decreases in cellular nucleic acid content, corresponding first to the extrusion of the nucleus and second to the loss of reticulum, characterized the later stages of erythroid development. These characteristics and instrumentation can be used to purify erythroid cells at various developmental stages.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2947644

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Expression of CD4 by human megakaryocytes.

Authors:  R S Basch; Y H Kouri; S Karpatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Immunohistochemical identification of erythroid precursors in paraffin embedded bone marrow sections: spectrin is a superior marker to glycophorin.

Authors:  Y Sadahira; A Kanzaki; H Wada; Y Yawata
Journal:  J Clin Pathol       Date:  1999-12       Impact factor: 3.411

3.  Defective erythropoiesis in transgenic mice expressing dominant-negative upstream stimulatory factor.

Authors:  Shermi Y Liang; Babak Moghimi; Valerie J Crusselle-Davis; I-Ju Lin; Michael H Rosenberg; Xingguo Li; John Strouboulis; Suming Huang; Jörg Bungert
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

4.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 5.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

6.  Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E.

Authors:  Jie Li; John Hale; Pooja Bhagia; Fumin Xue; Lixiang Chen; Julie Jaffray; Hongxia Yan; Joseph Lane; Patrick G Gallagher; Narla Mohandas; Jing Liu; Xiuli An
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

7.  K-Cl cotransporter gene expression during human and murine erythroid differentiation.

Authors:  Dao Pan; Theodosia A Kalfa; Daren Wang; Mary Risinger; Scott Crable; Anna Ottlinger; Sharat Chandra; David B Mount; Christian A Hübner; Robert S Franco; Clinton H Joiner
Journal:  J Biol Chem       Date:  2011-07-06       Impact factor: 5.157

8.  Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

Authors:  Elizabeth O Hexner; Cynthia Serdikoff; Mahfuza Jan; Cezary R Swider; Candy Robinson; Shi Yang; Thelma Angeles; Stephen G Emerson; Martin Carroll; Bruce Ruggeri; Pawel Dobrzanski
Journal:  Blood       Date:  2007-11-05       Impact factor: 22.113

9.  Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.

Authors:  Maria Ximeri; Athanasios Galanopoulos; Mirjam Klaus; Agapi Parcharidou; Krinio Giannikou; Maria Psyllaki; Argyrios Symeonidis; Vasiliki Pappa; Zafiris Kartasis; Dimitra Liapi; Eleftheria Hatzimichael; Styliani Kokoris; Penelope Korkolopoulou; Constantina Sambani; Charalampos Pontikoglou; Helen A Papadaki
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

10.  Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo.

Authors:  Jingping Hu; Jing Liu; Fumin Xue; Gregory Halverson; Marion Reid; Anqi Guo; Lixiang Chen; Azra Raza; Naomi Galili; Julie Jaffray; Joseph Lane; Joel Anne Chasis; Naomi Taylor; Narla Mohandas; Xiuli An
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.